|
Collaborative arrangements (Textuals 3) (Details) (USD $)
In Millions, unless otherwise specified |
12 Months Ended | 3 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 29, 2012
Takeda Pharmaceutical Company Limited [Member]
|
Dec. 31, 2008
Takeda Pharmaceutical Company Limited [Member]
Japanese Market Products [Member]
Molecule
|
Jun. 30, 2012
Takeda Pharmaceutical Company Limited [Member]
Other revenues [Member]
|
Dec. 31, 2012
Takeda Pharmaceutical Company Limited [Member]
Other revenues [Member]
|
Dec. 31, 2010
Takeda Pharmaceutical Company Limited [Member]
Other revenues [Member]
|
Dec. 31, 2012
Takeda Pharmaceutical Company Limited [Member]
Research and Development [Member]
|
Dec. 31, 2011
Takeda Pharmaceutical Company Limited [Member]
Research and Development [Member]
|
Dec. 31, 2010
Takeda Pharmaceutical Company Limited [Member]
Research and Development [Member]
|
Dec. 31, 2008
Takeda Pharmaceutical Company Limited [Member]
Milestone payments deferred or capitalized [Member]
|
Jun. 30, 2012
License arrangement for Motesanib with Takeda Pharmaceutical Company Limited [Member]
|
Dec. 31, 2012
Vectibix [Member]
Takeda Pharmaceutical Company Limited [Member]
|
Dec. 31, 2011
Vectibix [Member]
Takeda Pharmaceutical Company Limited [Member]
|
Dec. 31, 2010
Vectibix [Member]
Takeda Pharmaceutical Company Limited [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||||||||||
| Number of molecules developed and commercialized as per collaborations | 12 | ||||||||||||
| Milestone payments received | $ 55 | $ 300 | |||||||||||
| Amortization period of payments received and deferred under collaborative arrangements, in years | 20 years | ||||||||||||
| Deferred revenue as of the date of modification of the original arrangement | 230 | ||||||||||||
| Milestone payments received under arrangements | 3 | ||||||||||||
| Incremental cost to be recovered | 21 | ||||||||||||
| Revenue previously deferred recognized as a result of a material modification to the agreement | 206 | 24 | |||||||||||
| Cost recoveries | 74 | 83 | 91 | ||||||||||
| Royalties received on sales | $ 21 | $ 20 | $ 7 | ||||||||||